Advertisement

pp 1-21 | Cite as

Glucose Lowering Treatment Modalities of Type 2 Diabetes Mellitus

  • Asena Gökçay Canpolat
  • Mustafa ŞahinEmail author
Chapter
  • 52 Downloads
Part of the Advances in Experimental Medicine and Biology book series

Abstract

This chapter gives an overview of present knowledge and clinical aspects of antidiabetic drugs according to the recently available research evidence and clinical expertise.

Many agents are acting on eight groups of pathophysiological mechanisms, which is commonly called as “Ominous Octet” by DeFronzo. The muscle, liver and β-cell, the fat cell, gastrointestinal tract, α-cell, kidney, and brain play essential roles in the development of glucose intolerance in type 2 diabetic individuals (Defronzo, Diabetes 58:773–795, 2009).

A treatment paradigm shift is seen in the initiation of anti-hyperglycemic agents from old friends (meglitinides or sulphonylürea) to newer agents effecting on GLP-1 RA or SGLT-2 inhibitors. It is mostly about the other protective positive effects of these agents for kidney, heart, etc. Although there are concerns for the long term safety profiles; they are used widely around the World. The delivery of patient-centered care, facilitating medication adherence, the importance of weight loss in obese patients, the importance of co-morbid conditions are the mainstays of selecting the optimal agent.

Keywords

Acarbose Dipeptidyl peptidase 4 inhibitors Glucagon-like peptide 1 receptor agonists Glucose-lowering therapies Meglitinides Metformin Sodium-glucose transporter two inhibitors Sulphonylurea Thiazolidinediones 

References

  1. American Diabetes A (2019) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care 42:S90–S102Google Scholar
  2. Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298:194–206Google Scholar
  3. Anderson PO (2018) Treating diabetes during breastfeeding. Breastfeed Med 13:237–239Google Scholar
  4. Arslan MS, Tutal E, Sahin M et al (2017) Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes. Endocrine 55:410–415Google Scholar
  5. Bauman WA, Shaw S, Jayatilleke E, Spungen AM, Herbert V (2000) Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 23:1227–1231Google Scholar
  6. Bennett WL, Maruthur NM, Singh S et al (2011) Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 154:602–613Google Scholar
  7. Bergman AJ, Cote J, Yi B et al (2007) Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 30:1862–1864Google Scholar
  8. Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63:221–228Google Scholar
  9. Cahn A, Cefalu WT (2016) Clinical considerations for use of initial combination therapy in type 2 diabetes. Diabetes Care 39(Suppl 2):S137–S145Google Scholar
  10. Chamarthi B, Gaziano JM, Blonde L et al (2015) Timed bromocriptine-QR therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well-controlled type 2 diabetes mellitus. J Diabetes Res 2015:157698Google Scholar
  11. Committee on Practice B-O (2013) Practice bulletin no. 137: gestational diabetes mellitus. Obstet Gynecol 122:406–416Google Scholar
  12. Davies M, Chatterjee S, Khunti K (2016) The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol Adv Appl 8:61–81Google Scholar
  13. Davies MJ, D’Alessio DA, Fradkin J et al (2018) Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61:2461–2498Google Scholar
  14. Deeg MA, Tan MH (2008) Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies. PPAR Res 2008:520465Google Scholar
  15. Defronzo RA (2009) Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773–795Google Scholar
  16. DeFronzo RA, Goodman AM (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333:541–549Google Scholar
  17. Dubuisson O, Dhurandhar EJ, Krishnapuram R et al (2011) PPARgamma-independent increase in glucose uptake and adiponectin abundance in fat cells. Endocrinology 152:3648–3660Google Scholar
  18. Farrar D, Simmonds M, Bryant M et al (2017) Treatments for gestational diabetes: a systematic review and meta-analysis. BMJ Open 7:e015557Google Scholar
  19. Finneran MM, Landon MB (2018) Oral agents for the treatment of gestational diabetes. Curr Diab Rep 18:119Google Scholar
  20. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM (2007) A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30:389–394Google Scholar
  21. Gangopadhyay KK, Singh P (2017) Consensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment. Indian J Endocrinol Metab 21:341–354Google Scholar
  22. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL (1997) Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 103:491–497Google Scholar
  23. Garcia-Compean D, Gonzalez-Gonzalez JA, Lavalle-Gonzalez FJ, Gonzalez-Moreno EI, Maldonado-Garza HJ, Villarreal-Perez JZ (2015) The treatment of diabetes mellitus of patients with chronic liver disease. Ann Hepatol 14:780–788Google Scholar
  24. Glatstein MM, Djokanovic N, Garcia-Bournissen F, Finkelstein Y, Koren G (2009) Use of hypoglycemic drugs during lactation. Can Fam Physician 55:371–373Google Scholar
  25. Gross JL, Kramer CK, Leitao CB et al (2011) Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 154:672–679Google Scholar
  26. Haghvirdizadeh P, Mohamed Z, Abdullah NA, Haghvirdizadeh P, Haerian MS, Haerian BS (2015) KCNJ11: genetic polymorphisms and risk of diabetes mellitus. J Diabetes Res 2015:908152Google Scholar
  27. Hedrington MS, Davis SN (2019) Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes. Expert Opin Pharmacother 20:2229–2235Google Scholar
  28. Hsia DS, Grove O, Cefalu WT (2017) An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 24:73–79Google Scholar
  29. Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:140–149Google Scholar
  30. Jayaram S, Hariharan RS, Madhavan R, Periyandavar I, Samra SS (2010) A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes. J Assoc Physicians India 58:679–682, 687Google Scholar
  31. Karagiannis T, Boura P, Tsapas A (2014) Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf 5:138–146Google Scholar
  32. Kim W, Egan JM (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60:470–512Google Scholar
  33. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O (2000) A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 343:1134–1138Google Scholar
  34. Lee PG, Halter JB (2017) The pathophysiology of hyperglycemia in older adults: clinical considerations. Diabetes Care 40:444–452Google Scholar
  35. Liu Z, Ma S (2017) Recent advances in synthetic alpha-glucosidase inhibitors. ChemMedChem 12:819–829Google Scholar
  36. Lopez Vicchi F, Luque GM, Brie B, Nogueira JP, Garcia Tornadu I, Becu-Villalobos D (2016) Dopaminergic drugs in type 2 diabetes and glucose homeostasis. Pharmacol Res 109:74–80Google Scholar
  37. Luo S, Meier AH, Cincotta AH (1998) Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology 68:1–10Google Scholar
  38. Malaisse WJ (2003) Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2:401–414Google Scholar
  39. Moin T (2019) Should adults with prediabetes be prescribed metformin to prevent diabetes mellitus? Yes: high-quality evidence supports metformin use in persons at high risk. Am Fam Physician 100:134–135Google Scholar
  40. Moon MK, Hur KY, Ko SH et al (2017) Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. Korean J Intern Med 32:974–983Google Scholar
  41. Mukerji G, Feig DS (2017) Pharmacological management of gestational diabetes mellitus. Drugs 77:1723–1732Google Scholar
  42. Nauck MA (2004) Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res = Hormon- und Stoffwechselforschung = Hormones et metabolisme 36:852–858Google Scholar
  43. Nauck MA, Homberger E, Siegel EG et al (1986) Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63:492–498Google Scholar
  44. Nauck M, Frid A, Hermansen K et al (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84–90Google Scholar
  45. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471Google Scholar
  46. Ooi CP, Loke SC (2012) Colesevelam for type 2 diabetes mellitus. Cochrane Database Syst Rev 12:CD009361Google Scholar
  47. Phung OJ, Scholle JM, Talwar M, Coleman CI (2010) Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 303:1410–1418Google Scholar
  48. Pinto LC, Rados DV, Barkan SS, Leitao CB, Gross JL (2018) Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis. Sci Rep 8:782Google Scholar
  49. Raccah D (2017) Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues. Expert Opin Drug Saf 16:227–236Google Scholar
  50. Rohrborn D, Wronkowitz N, Eckel J (2015) DPP4 in diabetes. Front Immunol 6:386Google Scholar
  51. Rosenstock J, Kahn SE, Johansen OE et al (2019) Effect of Linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322(21):1155–1166Google Scholar
  52. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP, Mi GTI (2008) Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 358:2003–2015Google Scholar
  53. Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM (2011) Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. Diabetes Care 34:2279–2284Google Scholar
  54. Russell-Jones D, Cuddihy RM, Hanefeld M et al (2012) Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 35:252–258Google Scholar
  55. Saeedi P, Petersohn I, Salpea P et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 157:107843Google Scholar
  56. Sahin M, Corapcioglu D (2016) Metformin versus placebo in obese pregnant women without diabetes. N Engl J Med 374:2501Google Scholar
  57. Sahin M, Bakiner O, Ertugrul D, Guvener ND (2005) Creatine kinase elevation in a patient taking rosiglitazone. Diabet Med 22:1624–1625Google Scholar
  58. Sahin M, Tutuncu NB, Ertugrul D, Tanaci N, Guvener ND (2007) Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. J Diabetes Complicat 21:118–123Google Scholar
  59. Sansome DJ, Xie C, Veedfald S, Horowitz M, Rayner CK, Wu T (2019) Mechanism of glucose-lowering by metformin in type 2 diabetes: role of bile acids. Diabetes Obes Metab 22(2):141–148Google Scholar
  60. Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326Google Scholar
  61. Singh M, Kumar A (2018) Risks associated with SGLT2 inhibitors: an overview. Curr Drug Saf 13:84–91Google Scholar
  62. Sun X, Zhang Z, Ning H, Sun H, Ji X (2017) Sitagliptin down-regulates retinol-binding protein 4 and reduces insulin resistance in gestational diabetes mellitus: a randomized and double-blind trial. Metab Brain Dis 32:773–778Google Scholar
  63. Thule PM, Umpierrez G (2014) Sulfonylureas: a new look at old therapy. Curr Diab Rep 14:473Google Scholar
  64. Tsimihodimos V, Filippas-Ntekouan S, Elisaf M (2018) SGLT1 inhibition: pros and cons. Eur J Pharmacol 838:153–156Google Scholar
  65. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853Google Scholar
  66. Vaughan EM, Johnston CA, Hyman DJ, Hernandez DC, Hemmige V, Foreyt JP (2017) Dual therapy appears superior to monotherapy for low-income individuals with newly diagnosed type 2 diabetes. J Prim Care Community Health 8:305–311Google Scholar
  67. Wang YW, He SJ, Feng X et al (2017) Metformin: a review of its potential indications. Drug Des Devel Ther 11:2421–2429Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Endocrinology and MetabolismAnkara University School of MedicineAnkaraTurkey

Personalised recommendations